98%
921
2 minutes
20
Purpose: Follicular and papillary thyroid cancers are prevalent endocrine tumors in children and adolescents. This study seeks to highlight distinctions between papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) to inform subtype-specific guidelines.
Patients And Methods: Utilizing data from the SEER database, this study contrasts the clinical features, survival rates, causes of death, TNM staging, and surgical interventions for pediatric and adolescent patients diagnosed with PTC and FTC from 2000 to 2020.
Results: We analyzed 3068 pediatric and adolescent patients with differentiated thyroid cancer (DTC). Since 2005, PTC incidence has increased, while FTC remains stable. Both subtypes exhibit excellent survival rates; FTC shows near-perfect outcomes, and PTC's overall survival (OS) at 2, 5, and 10 years is 99.6, 99.2, and 98.5%, respectively. Thyroid cancer accounted for only 20.9% of deaths among PTC patients. Significant differences in T and N staging were observed. Regarding surgery, 70% of FTC patients underwent total or near-total thyroidectomy compared to 90% of PTC patients. Lymph node dissection was performed in 41.7% of FTC and 77.5% of PTC patients, indicating distinct surgical approaches.
Conclusion: Pediatric and adolescent patients with FTC and PTC have excellent prognoses. The extent of thyroidectomy and criteria for prophylactic central lymph node dissection should be tailored specifically for FTC and PTC, rather than generalizing under DTC.
Clinical Trial Information: NCT06592118.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00383-025-05990-3 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Information Network Center, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: Increasing detection of low-risk papillary thyroid carcinoma (PTC) is associated with overdiagnosis and overtreatment. N6-methyladenosine (mA)-mediated microRNA (miRNA) dysregulation plays a critical role in tumor metastasis and progression. However, the functional role of mA-miRNAs in PTC remains unclear.
View Article and Find Full Text PDFInt J Hyperthermia
December 2025
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Objective: This study aimed to evaluate the efficacy and safety of US-guided thermal ablation (TA) for solitary papillary thyroid carcinoma (PTC) in elderly patients.
Materials And Methods: This retrospective study included 91 elderly patients with solitary PTC who were treated with TA. The primary outcome was disease progression.
Clin Endocrinol (Oxf)
September 2025
Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Improved cancer survival rates have highlighted second primary malignancies (SPMs), with the thyroid gland being one of the most common organs developing SPMs in cancer survivors. Second primary papillary thyroid carcinoma (2-PTC) is the predominant type, yet it remains poorly understood. This study aims to delineate the clinicopathological features and survival outcomes of 2-PTC and assess the efficacy of postoperative radioactive iodine therapy (post-RAIT) in reducing mortality risks in intermediate-risk 2-PTC patients.
View Article and Find Full Text PDFJ Pediatr Surg
September 2025
First Department of Pediatric Surgery, Aristotle University of Thessaloniki, General Hospital "G. Gennimatas", Thessaloniki, Greece.
Background: Thyroid cancer in pediatric patients is distinct from adult-onset thyroid cancer due to differences in disease presentation, management and outcomes. This meta-analysis delves into contemporary data on managing pediatric differentiated thyroid cancer (DTC), assessing outcomes, such as recurrence and mortality, in children with radical total thyroidectomy versus the more conservative lobectomy approach.
Methods: MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), trial registry websites (ClinicalTrials.
World J Surg
September 2025
Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.